In The News
ConstructionPRO Test 1
ConstructionPRO Test 2
ConstructionPRO Test 3
ConstructionPRO Test 4
ConstructionPRO Test 5
ConstructionPRO Test 6
ConstructionPRO Test 7
High Court rejects Qantas appeal in ground crew sacking case
I’m afraid AI can’t do that: Law firms say smart tech uses limited
Lawyer’s defamation case fails serious harm test, judge finds
Dr Reddy’s must warn Celgene of plans to sell generic blockbuster cancer drug
Bristol-Myers Squibb 2021-12-07 2:55 pm By Cindy Cameronne Sydney
Please login to bookmark Close

Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au